Free Radical Biology & Medicine 2004, 37: 768–784.CrossRef 20. Ozaki Deshpande SS, Angkow P, Bellan J, Lowenstein CJ, Dinauer MC, Goldschmidt Clermont PJ, lrani K: Inhibition of the Rac1 GTPase protects against nonlethal ischemia/reperfusion-induced necrosis and apoptosis in vivo. FASEB J 2000, 14: 418–429. 21. Faris Apoptosis inhibitor SL, SRT2104 purchase Rinckel LA, Huang J, Hong YR, Kleinberg ME: Phagocyte NADPH oxidase p67-phox possesses a novel carboxyl
terminal binding site for the GTPases Rac 2 and Cdc42. Biochem Biophys Res Commun 1998, 247: 271–276.CrossRefPubMed 22. Yeh LH, Park YJ, Hansalia RJ, Ahmed IS, Deshpande SS, Goldschmidt Clemont PJ, Irani K, Alevriadou BR: Shear-induced tyrosine phosphorylation in endothelial cells requires Rac1-dependent production of ROS. AM J Physiol 1999, 276: C838-C847.PubMed 23. Wang Z, Castresana MR, Newman WH:
Reactive oxygen and NF-kappa B in VEGF-induced migration of human vascular smooth muscle cells. Biochem Biophys Res Commun 2001, 285: 669–674.CrossRefPubMed 24. Kosai K, Matsumoto K, Funakoshi H, Nakamura T: Hepatocyte growth factor prevents endotoxin-induced lethal hepatic failure in mice. Hepatology 1999, 30: 151–159.CrossRefPubMed 25. Ozaki M, Haga S, Zhang HG, lrani K, Suzuki S: Inhibitions of hypoxia/reoxygenation-induced oxidative stress in HGF-stimulated SGC-CBP30 anti-apoptotic signaling: role of PI3-K and Akt kinase upon rac1. Cell Death and Differentiation 2003, 10: 508–515.CrossRefPubMed 26. Miura Y, Kozuki Y, Yagasaki K: Potentiation of invasive activity of hepatoma cells by reactive oxygen species is mediated by autocrine/paracrine loop of hepatocyte growth factor. Biochem Biophys Res Commun 2003, 305: 160–165.CrossRefPubMed 27. Xing RH, Rabbani SA: Overexpression of urokinase receptor in breast cancer cells result in increased tumor invasion, growth and mafosfamide metastasis. Int J Cancer 1996, 67: 423–9.CrossRefPubMed 28. Duggan C, Maguire T, McDermott E, O’Higgins N, Fennelly JJ, Duffy MJ: Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer 1995, 61: 597–600.CrossRefPubMed 29. Yang JL, Seetoo DG, Wang Y, Ranson M, Bemey CR, Ham JM, Russell PJ, Crowe PJ: Urokinase-type
plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets. Int J Cancer 2000, 20: 431–9.CrossRef 30. Solomayer EF, Kiel IJ, Wallwlener D, Bode S, Meyberg G, Sillem M, Gollan CH, Kramer MD, Krainick U, Baster G: Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer. Br J Cancer 1997, 76: 812–8.PubMed 31. Bouchetm C, Spyratos F, Hacène K, Furcos L, Bécette V, Oglobine J: Prognostic value of urokinase plasminogen activator in primary breast carcinoma: comparison of two immunoassay methods. Br J Cancer 1998, 77 (9) : 1495–501. 32.